| __timestamp | Halozyme Therapeutics, Inc. | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 79838000 |
| Thursday, January 1, 2015 | 29245000 | 121816000 |
| Friday, January 1, 2016 | 33206000 | 117633000 |
| Sunday, January 1, 2017 | 31152000 | 4577000 |
| Monday, January 1, 2018 | 10136000 | 12670000 |
| Tuesday, January 1, 2019 | 45546000 | 12135000 |
| Wednesday, January 1, 2020 | 43367000 | 18942000 |
| Friday, January 1, 2021 | 81413000 | 32328000 |
| Saturday, January 1, 2022 | 139304000 | 44678000 |
| Sunday, January 1, 2023 | 192361000 | 65486000 |
| Monday, January 1, 2024 | 159417000 |
Infusing magic into the data realm
In the ever-evolving biotech industry, understanding cost structures is crucial. From 2014 to 2023, Halozyme Therapeutics, Inc. and PTC Therapeutics, Inc. have shown distinct trajectories in their cost of revenue. Halozyme's cost of revenue surged by over 740% from 2014 to 2023, peaking in 2023. This reflects their aggressive expansion and scaling strategies. In contrast, PTC Therapeutics experienced a more volatile path, with a significant drop in 2017, followed by a gradual recovery, ending with a 22% increase from 2014 to 2023. This fluctuation highlights the challenges PTC faces in managing production costs amidst market pressures. These insights underscore the importance of strategic cost management in maintaining competitive advantage in the biotech sector. As investors and stakeholders analyze these trends, they gain a clearer picture of each company's operational efficiency and market positioning.
Cost of Revenue: Key Insights for Johnson & Johnson and Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Novartis AG and Halozyme Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for United Therapeutics Corporation and Halozyme Therapeutics, Inc.
Incyte Corporation vs PTC Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Insmed Incorporated and PTC Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Evotec SE's Expenses
Cost of Revenue: Key Insights for Amneal Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
Cost of Revenue Trends: PTC Therapeutics, Inc. vs Vericel Corporation
Analyzing Cost of Revenue: PTC Therapeutics, Inc. and Celldex Therapeutics, Inc.